Krystal Biotech (NASDAQ:KRYS) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research note published on Saturday.

Several other research firms have also commented on KRYS. Wolfe Research assumed coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock. The Goldman Sachs Group lifted their price target on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Guggenheim lifted their price target on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a report on Tuesday. Finally, Bank of America lifted their price target on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $305.71 on Friday. The stock’s fifty day moving average is $263.06 and its two-hundred day moving average is $248.61. The firm has a market capitalization of $9.01 billion, a P/E ratio of 40.87 and a beta of 0.50. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $306.10.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. On average, equities analysts forecast that Krystal Biotech will post 7.98 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the sale, the chief accounting officer directly owned 22,366 shares of the company’s stock, valued at approximately $5,985,141.60. This trade represents a 3.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Janney sold 11,803 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $275.59, for a total value of $3,252,788.77. Following the sale, the director directly owned 73,293 shares of the company’s stock, valued at $20,198,817.87. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 over the last 90 days. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its position in shares of Krystal Biotech by 17.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,985 shares of the company’s stock worth $513,000 after purchasing an additional 289 shares during the last quarter. AlphaCentric Advisors LLC grew its position in Krystal Biotech by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 1,918 shares of the company’s stock valued at $495,000 after acquiring an additional 105 shares in the last quarter. SEB Asset Management AB acquired a new position in Krystal Biotech in the 1st quarter valued at about $11,971,000. Hanseatic Management Services Inc. acquired a new position in Krystal Biotech in the 1st quarter valued at about $774,000. Finally, Assetmark Inc. acquired a new position in Krystal Biotech in the 1st quarter valued at about $816,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.